Scribe Therapeutics Inc.(SCTX)

Biotechnology · Alameda, CA

$16.51+0.30 (+1.85%)

Delayed quote: Oct 6, 2026, 1:20 PM EDT

Operating Cash Flow Yield: N/A

Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The operating cash flow yield is N/A as of 2026-10-06T17:23:31.505Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:23:31.505Z.

Quote observation: 2026-10-06T17:20:06.000Z. Amounts in USD. The price header may show a later quote.

TTM operating cash flow: N/A
Quote market capitalization: 267,164,985

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

P/OCF Ratio|FCF Yield|Earnings Yield|EBITDA Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SCTX Operating Cash Flow Yield Metrics

OPERATING CASH FLOW YIELD

N/A

SCTX Competitors' Operating Cash Flow Yield

SCTX

Scribe Therapeutics Inc.

Current

Market Cap

$267.16M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TLSI

TriSalus Life Sciences, Inc.

vs SCTX

Market Cap

$269.06M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OSUR

OraSure Technologies, Inc.

vs SCTX

Market Cap

$265.07M

Operating Cash Flow Yield

N/A

TTM Avg

17.72%

3Y Avg

21.01%

5Y Avg

14.11%

TMCI

Treace Medical Concepts, Inc.

vs SCTX

Market Cap

$270.52M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SABS

SAB Biotherapeutics, Inc.

vs SCTX

Market Cap

$270.68M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FATE

Fate Therapeutics, Inc.

vs SCTX

Market Cap

$271.10M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EPRX

Eupraxia Pharmaceuticals Inc.

vs SCTX

Market Cap

$264.16M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RCKT

Rocket Pharmaceuticals, Inc.

vs SCTX

Market Cap

$270.25M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IKT

Inhibikase Therapeutics, Inc.

vs SCTX

Market Cap

$263.41M

Operating Cash Flow Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EYPT

EyePoint Pharmaceuticals, Inc.

vs SCTX

Market Cap

$262.74M

Operating Cash Flow Yield

N/A

TTM Avg

2.42%

3Y Avg

2.42%

5Y Avg

2.42%

NAME	MARKET CAP	OPERATING CASH FLOW YIELD	TTM	3Y	5Y
Scribe Therapeutics Inc. (SCTX)	$267.16M	N/A	N/A	N/A	N/A
TriSalus Life Sciences, Inc. (TLSI)vs ›	$269.06M	N/A	N/A	N/A	N/A
OraSure Technologies, Inc. (OSUR)vs ›	$265.07M	N/A	17.72%	21.01%	14.11%
Treace Medical Concepts, Inc. (TMCI)vs ›	$270.52M	N/A	N/A	N/A	N/A
SAB Biotherapeutics, Inc. (SABS)vs ›	$270.68M	N/A	N/A	N/A	N/A
Fate Therapeutics, Inc. (FATE)vs ›	$271.10M	N/A	N/A	N/A	N/A
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$264.16M	N/A	N/A	N/A	N/A
Rocket Pharmaceuticals, Inc. (RCKT)vs ›	$270.25M	N/A	N/A	N/A	N/A
Inhibikase Therapeutics, Inc. (IKT)vs ›	$263.41M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$262.74M	N/A	2.42%	2.42%	2.42%

Operating Cash Flow Yield Formula & Definition

OCF Yield = TTM Operating Cash Flow / Market Cap

Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Operating Cash Flow Yield: N/A

SCTX Operating Cash Flow Yield Metrics

SCTX Competitors' Operating Cash Flow Yield

Operating Cash Flow Yield Formula & Definition

Related Metrics